Log in or Sign up for Free to view tailored content for your specialty!
Rheumatology News
![Shared decision-making boosts trust in physicians among patients with lupus](/~/media/slack-news/stock-images/cardiology/d/doctor-female-patient-middle-age_adobe.jpg?w=400)
Shared decision-making boosts trust in physicians among patients with lupus
Practicing shared decision-making increases overall trust in health care providers among patients with systemic lupus erythematosus, according to data published in Arthritis Care & Research.
Risk for myalgic encephalomyelitis/chronic fatigue syndrome no greater after COVID-19
![Risk for myalgic encephalomyelitis/chronic fatigue syndrome no greater after COVID-19](/~/media/slack-news/rheumatology/misc/infographics/2024/rh0824unger_graphic_01.jpg?w=400)
COVID-19 does not increase patients’ risk for developing myalgic encephalomyelitis/chronic fatigue syndrome during the 1-year period post infection, according to a registry study published in JAMA Network Open.
FDA fast tracks CAR T-cell therapy for refractory lupus in anticipation of phase 1 trial
![FDA fast tracks CAR T-cell therapy for refractory lupus in anticipation of phase 1 trial](/~/media/slack-news/generic-infographics/2023/generic-fda-news.jpg?w=400)
The FDA has granted fast track designation to CB-010, an allogeneic anti-CD19 CAR T-cell therapy from Caribou Biosciences, for refractory systemic lupus erythematosus ahead of a planned phase 1 trial, according to a press release.
Log in or Sign up for Free to view tailored content for your specialty!
Safety checklist compiles clinically important DMARD warnings in one place
![Safety checklist compiles clinically important DMARD warnings in one place](/~/media/slack-news/rheumatology/misc/infographics/2024/rh0824skaarup_graphic_01.jpg?w=400)
Nearly all biologic and targeted synthetic disease-modifying antirheumatic drugs come with infection or malignancy warnings from U.S. or European regulatory agencies, according to a study published in Drug Safety.
Risks for bias high, unclear in 80% of AI models for predicting RA treatment response
![Risks for bias high, unclear in 80% of AI models for predicting RA treatment response](/~/media/slack-news/stock-images/general/a/ai-doctor-with-laptop.jpg?w=400)
The use of machine learning models to predict treatment response in rheumatoid arthritis is increasing, though approximately 80% show “unclear and high risk of bias,” according to data published in Seminars in Arthritis and Rheumatism.
Legislation seeks to minimize prior authorizations that ‘deny, delay and aggravate’
![Legislation seeks to minimize prior authorizations that ‘deny, delay and aggravate’](/~/media/slack-news/rheumatology/mugs/l/levin_robert_2019.jpg?w=80)
Attempts to curtail prior authorizations for patients insured by Medicare Advantage plans have failed in back-to-back legislative sessions in 2019 and 2021, but a new bill has some experts hopeful that the third time is a charm.
FDA approves new label for Gloperba enabling precision dosing for gout prophylaxis
![FDA approves new label for Gloperba enabling precision dosing for gout prophylaxis](/~/media/slack-news/stock-images/rheumatology/f/fda_product_healio_23007093.jpg?w=400)
The FDA has approved an updated label for Gloperba, an oral liquid colchicine formulation, allowing for precision dosing, according to a press release from Scilex Holding Company.
Systemic immune-inflammation index predicts mortality in rheumatoid arthritis
![Systemic immune-inflammation index predicts mortality in rheumatoid arthritis](/~/media/slack-news/rheumatology/misc/infographics/2024/rh0724wang_graphic_01.jpg?w=400)
Systemic immune-inflammation index levels may be used to predict all-cause and cardiovascular mortality among patients with rheumatoid arthritis, according to data published in Scientific Reports.
Lupus risk higher after mRNA vaccination against COVID-19
![Lupus risk higher after mRNA vaccination against COVID-19](/~/media/slack-news/rheumatology/misc/infographics/2024/rh0724jung_graphic_01.jpg?w=400)
Patients who received an mRNA COVID-19 vaccine demonstrated a 1.16-fold higher long-term risk for systemic lupus erythematosus, while a booster was linked to higher risk for psoriasis and rheumatoid arthritis, according to data.
Women with high ultraprocessed food intake have 56% greater lupus risk
![Women with high ultraprocessed food intake have 56% greater lupus risk](/~/media/slack-news/rheumatology/misc/infographics/2024/rh0824rossato_abstract.png?w=400)
Women who consume the greatest daily amount of ultraprocessed foods on average demonstrate a 56% higher risk for systemic lupus erythematosus, according to data published in Arthritis Care & Research.
-
Headline News
Mental health of health workers remains a major concern following pandemic
September 05, 20244 min read -
Headline News
How PCPs can use social drivers of health 'to affect positive change' in their communities
September 04, 20246 min read -
Headline News
QWINT: Once-weekly basal insulin noninferior to daily insulins in type 2 diabetes
September 05, 20243 min read
-
Headline News
Mental health of health workers remains a major concern following pandemic
September 05, 20244 min read -
Headline News
How PCPs can use social drivers of health 'to affect positive change' in their communities
September 04, 20246 min read -
Headline News
QWINT: Once-weekly basal insulin noninferior to daily insulins in type 2 diabetes
September 05, 20243 min read